Related references
Note: Only part of the references are listed.Deficiency of Endogenous Acute Phase Serum Amyloid A Does Not Affect Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice
Maria C. De Beer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice hut not in the circulation: implications for a clinical test
Nicholas S. Kirkby et al.
FASEB JOURNAL (2013)
LC-MS/MS Confirms That COX-1 Drives Vascular Prostacyclin Whilst Gene Expression Pattern Reveals Non-Vascular Sites of COX-2 Expression
Nicholas S. Kirkby et al.
PLOS ONE (2013)
A vasoconstrictor role for cyclooxygenase-1-mediated prostacyclin synthesis in mouse renal arteries
Bin Liu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Cyclooxygenase-2-Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a Sirtuin-1-Dependent-Manner
Silvia S. Barbieri et al.
CIRCULATION (2012)
Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries
Bin Liu et al.
EXPERIMENTAL PHYSIOLOGY (2012)
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice
Zhou Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system
Nicholas S. Kirkby et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Quantitative 3-Dimensional Imaging of Murine Neointimal and Atherosclerotic Lesions by Optical Projection Tomography
Nicholas S. Kirkby et al.
PLOS ONE (2011)
NSAID Use Selectively Increases the Risk of Non-Fatal Myocardial Infarction: A Systematic Review of Randomised Trials and Observational Studies
Luis Alberto Garcia Rodriguez et al.
PLOS ONE (2011)
Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
Patricia McGettigan et al.
PLOS MEDICINE (2011)
Targeted Deletions of Cyclooxygenase-2 and Atherogenesis in Mice
Yiqun Hui et al.
CIRCULATION (2010)
Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice
Jonathan M. Gitlin et al.
CARDIOVASCULAR RESEARCH (2009)
COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs
Timothy D. Warner et al.
LANCET (2008)
Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice
Roland Klingenberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
COX-2 inhibitors and cardiovascular risk
Colin D. Funk et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
A novel anti-atherogenic role for COX-2-potential mechanism for the cardiovascular side effects of COX-2 inhibitors
Ajay Narasimha et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association
Elliott M. Antman et al.
CIRCULATION (2007)
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk
Edwin S. L. Chan et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Balancing prostanoid activity in the human vascular system
Nicholas A. Flavahan
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events
Jane A. Mitchell et al.
FASEB JOURNAL (2006)
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Y Cheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs
JA Mitchell et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse - Model characterization and effects of pravastatin treatment
J Johnson et al.
CIRCULATION (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cyclooxygenases, thromboxane, and atherosclerosis -: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism
KM Egan et al.
CIRCULATION (2005)
Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis
OA Belton et al.
CIRCULATION (2003)
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice
D Rott et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice
M Olesen et al.
SCANDINAVIAN CARDIOVASCULAR JOURNAL (2002)
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice
ME Burleigh et al.
CIRCULATION (2002)
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells
MA Hernandez-Presa et al.
ATHEROSCLEROSIS (2002)
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits
E Wong et al.
ATHEROSCLEROSIS (2001)
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
SL Tilley et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
D Praticò et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries
V Stemme et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2000)
NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
JL Wallace et al.
GASTROENTEROLOGY (2000)
Share Paper
